Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.102589
Revised: January 6, 2025
Accepted: January 20, 2025
Published online: March 27, 2025
Processing time: 124 Days and 17.2 Hours
Bleeding ectopic varices located in the small bowel (BEV-SB) caused by portal hypertension (PH) are rare and life-threatening clinical scenarios. The current management of BEV-SB is unsatisfactory. This retrospective study analyzed four cases of BEV-SB caused by PH and detailed the management of these cases using enteroscopic injection sclerotherapy (EIS) and subsequent interventional radio
To analyze the management of BEV-SB caused by PH and develop a treatment algorithm.
This was a single tertiary care center before-after study, including four patients diagnosed with BEV-SB secondary to PH between January 2019 and December 2023 in the Air Force Medical Center. A retrospective review of the medical re
Four out of 519 patients diagnosed with PH were identified as having BEV-SB. The management duration of each phase was 20 person-months, 42 person-months, and 77 person-months, respectively. The four patients received a total of eight and five person-times of EIS and IR treatment, respectively. All patients exhibited recurrent gastrointestinal bleeding following the first EIS, while no further instances of gastrointestinal bleeding were observed after IR treatment. The transfusions administered during each phase were 34, 31, and 3.5 units of red blood cells, and 13 units, 14 units, and 1 unit of plasma, respectively.
EIS may be effective in achieving hemostasis for BEV-SB, but rebleeding is common, and IR aiming to reduce portal pressure gradient may lower the rebleeding rate.
Core Tip: Bleeding ectopic varices located in the small bowel (BEV-SB) caused by portal hypertension is a rare, life-threatening clinical scenario. This retrospective study presented the treatment experience using enteroscopic injection sclerotherapy (EIS) and subsequent interventional radiology (IR) for BEV-SB. From January 2019 to December 2023, 4 of 519 patients with portal hypertension were identified as having BEV-SB. The management duration of phases from the first episode of BEV-SB to the first EIS, from the first EIS to the first IR, and from the first IR to December 2023 were 20 person-months, 42 person-months, and 77 person-months, respectively. The corresponding transfusions at each phase were 34 units, 31 units, and 3.5 units of red blood cells and 13 units, 14 units, and 1 unit of plasma, respectively. After the comprehensive management, no further gastrointestinal bleeding was observed. We conclude that EIS may be effective in achieving hemostasis in BEV-SB, although rebleeding is common, and IR aiming to reduce portal venous pressure may lower the rebleeding rate.